Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
Swiss CDMO Lonza plans to invest an undisclosed sum to establish drug product manufacturing capabilities at its site in Guangzhou, China. The investment in the central...
Lonza has completed the carve-out of its Specialty Ingredients business as LSI and appointed a management team led by CEO Mark Doyle, a former DuPont and DowDuPont chief...
Lonza is investing 20 million Swiss francs in an expansion of its API development and manufacturing facility at Nansha, China. The Basel-based CDMO said the expanded...
Swiss CDMO Lonza is collaborating with Swedish pharma SelectImmune to develop processes for NlpD, a novel immunotherapy protein that could provide an alternative to...
As it ramps up production on three continents, US Covid-19 vaccine manufacturer Moderna is expanding its collaborations with CDMO suppliers in Europe, the US and Asia. At...
In two major new investments at its sites in Visp, Switzerland, and Portsmouth New Hampshire, USA, Swiss CDMO Lonza said it will spend 850 million Swiss francs to expand...
Swiss CDMO Lonza and US vaccine maker Moderna have extended and deepened their collaboration on the US biotech’s mRNA- based Covid-19 shot. The new agreement, which calls...
